– Dr. De Backer to assume CEO role on April 3, 2023 – Dr. De Backer brings to her new role more than two decades of broad international leadership experience, including a strong track record in global ...
– Virtual R&D Day webcast scheduled for today, Wednesday, April 27, at 12:00 pm ET / 9:00 am PT – SAN FRANCISCO, April 27, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today ...
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Mark D. Eisner, M.D., M.P.H. will join the company as Executive Vice President and Chief Medical Officer (CMO ...
GSK is walking away from a core piece of its $345 million bet on Vir Biotechnology. The partners have ended their collaboration on anti-influenza antibodies, freeing Vir to “actively” pitch the ...
Vir Biotechnology’s sidelined hepatitis B candidate, designed to serve as a “functional cure,” has failed to achieve the efficacy results hoped for in a midstage study. The investigational combo of ...
SAN FRANCISCO, May 15, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (VIR) today announced the appointment of Jeff Calcagno, M.D., as Executive Vice President and Chief Business Officer. Dr.
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Jennifer Towne, Ph.D., as Executive Vice President and Chief Scientific Officer, effective ...
SAN FRANCISCO, June 07, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that five abstracts highlighting new data from the Company’s broad hepatitis portfolio addressing ...
Vir Biotechnology Inc. VIR said Thursday a mid-stage trial of a treatment for symptomatic flu failed to meet its main goals, sending the stock down 40% premarket. The Phase 2 trial dubbed Peninsula ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results